TNK-tPA

TNK-tPA

Cardiology A proprietary bioengineered agent administered as an IV bolus, which dissolves coronary clots without interfering with other clotting factors. See ASSENT I, Bolus thrombolytic.
References in periodicals archive ?
Tenders are invited for Tenectiplase Tnk-Tpa 40Mg Inj Vial - With Diluent
ENTIRE (ENoxaparin and TNK-tPA with or without GP IIb/IIIa Inhibitor as REperfusion strategy in ST elevation MI), also referred to as TIMI 23, will examine TIMI flows through coronary angiography, utilizing varying dosing regimens of TNKase(TM) (Tenecteplase), the low-molecular-weight heparin Lovenox, the anti-platelet agent ReoPro, and heparin sodium.
NYSE: GNE) announced today positive preliminary results from two Phase II trials of second-generation tissue plasminogen activator (t-PA) -- called TNK-tPA -- in acute myocardial infarction.
TNK-tPA is a selectively mutated version of natural t-PA.
The TIMI 10B trial evaluated the efficacy of TNK-tPA versus Activase at restoring blood flow in coronary arteries at 90-minutes following treatment.
The ASSENT trial examined the safety of TNK-tPA, evaluating the rates of intracranial hemorrhage (ICH) and mortality in patients treated with the same doses of TNK-tPA compared to Activase as in the TIMI 10B trial.
We are very pleased with the preliminary results which show that TNK-tPA is a promising new single-bolus thrombolytic agent," said Arthur D.
Most recently, he was development project team leader for a second generation thrombolytic, Genentech's TNK-tPA compound.